drugset / Trial / NCT04309084

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

NCT04309084

Phase 1 Unknown 29 enrolled Celularity Incorporated
NaSequentialOpen-labelTreatment

Summary

This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT). The safety of this treatment will be evaluated, and researchers will want to learn if NK cells will help in treating Multiple Myeloma.

Timeline

Start
2020-05-12
Primary completion
2023-01-31
Completion
2023-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CYNK-001 Cell therapy